AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00004857 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: 30 mg subQ injection tiw for 6 weeks
Study NCT00004857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 25mg/sq m/day IV infusion x 5 days Wks 1, 5, 9, and 13
Study NCT04102345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender Aromatherapy
Description: Commercially available lavender essential oil and diffuser.
Study NCT04102345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: Physician directed, pre-prescribed. Study team does not prescribe zolpidem.
Study NCT04547933 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bladder diary
Description: A 3-day bladder diary recording daily drinking fluid amount, daily urine amount, urgency and urinary incontinence episodes.
Study NCT01215903 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish gelatin and omega-3 polyunsaturated fatty acid
Study NCT01215903 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acid
Study NCT04055545 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HIIT
Description: * 5 min. warm up~* 10 × 60 seconds burst~* 60 seconds recovery after each burst~* Burst phase: HRR >90%~* Recovery phase: HRR btw. 30-39%~* 5 min. cool down
Study NCT04055545 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MICT
Description: * 5 min. warm up~* 20 min. continuous cycling: HRR btw. 40% - 59%~* 5 min. cool down
Study NCT04087317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 Mg Oral Tablet
Description: The drug will be administrated when the woman arrive to the maternity unit, and every 6 hours thereafter, for first 24 hours following delivery.
Study NCT04100044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Counseling
Description: Meet with physical therapist
Study NCT04100044 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Receive personalized home exercise intervention
Study NCT04100044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Description: Ancillary studies
Study NCT04100044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04016064 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Er:YAG LASER, Nd:YAG laser, elctrosurgery, conventional surgery
Description: 1. Er: YAG laser (Fotana AT Fidelis III, Ljubljana, Slovenia) 200 mj, 10 Hz, 2 Watt and VLP (long pulse, 1000 μs); 1.3 mm diameter, 8 mm long cylindrical, a sapphire tip was used with air cooling and water irrigation.~2. Nd: YAG laser (Fotana AT Fidelis III, Ljubljana, Slovenia) was applied at 4 watts, 50 Hz, 300 μm microfiber tip and SP (short pulse: 180 μs) settings.~3. Electrosurgical (Servotome Classic System, High Frequency Surgical Equipment, Satelec, France).~4. Conventional surgical method was applied with hand instruments and gingivectomy knives.
Study NCT00583154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI-801
Description: Dose 3
Study NCT00583154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI-801
Description: Dose 4
Study NCT04016610 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soliton's Acoustic Scar Reduction (SAR)
Description: Treatment of keloid scars for the temporary improvement in appearance.
Study NCT02705963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Each tablet is 2mg trametinib to be taken orally once daily.
Study NCT02705963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Each tablet is 0.5mg trametinib to be taken orally once daily. 0.5mg tablets may be used if a dose reduction is required.
Study NCT02705963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Contraceptive (1mg norethindrone, 0.035mg ethinyl estradiol)
Description: Combined oral contraceptive to be taken orally once daily.
Study NCT02028143 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biosense Webster irrigated tip catheter
Description: The second group (study group) will have the ICE catheter placed through one of two existing 8F sheaths already in the left atrium. The ICE catheter will be exchanged in the sheath utilizing the lasso multipolar mapping catheter during left pulmonary vein ablation lines. During exchange, suction and irrigation techniques will be utilized to avoid any air or thrombus embolization. All patients will have standard anticoagulation during the procedure with heparin infusion adjusted to an activated clotting time (ACT) of 350-400. The left sided ICE catheter will be adjusted to visualize left sided structures, ablation tip and tissue interface, and adjacent noncardiac structures such as the esophagus during radiofrequency ablation of the left pulmonary vein system.
Study NCT04087317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400Mg Tab
Description: The drug will be administrated when the woman arrive to the maternity unit, and every 6 hours thereafter, for first 24 hours following delivery.
Study NCT04087317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 Mg Oral Tablet
Description: The drug will be administrated after a maternal request, by at least 6 hours apart between dosages.
Study NCT04087317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: The drug will be administrated after a maternal request, by at least 6 hours apart between dosages.
Study NCT04087317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIR
Description: At any time, if a woman experienced pain despite the prescribed treatment, the next line of treatment was MIR (morphine immediate release, 10 mg tablet).
Study NCT03559725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VLN menthol cigarettes (A)
Description: 0.4mg nicotine / g tobacco king size filter menthol cigarette
Study NCT03559725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Brand Menthol Cigarettes (B)
Description: Usual brand king size menthol cigarettes
Study NCT02028143 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biosense Webster irrigated tip catheter
Description: Group 1 will receive standard pulmonary vein isolation (PVI) procedure utilizing intracardiac guided ultrasound (ICE) placed within the right atrium via the femoral vein.
Study NCT02028143 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation
Study NCT02028143 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICE catheter placed through one of two existing 8F sheaths
Study NCT01548287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5213
Description: AZD5213 doseA daily
Study NCT01548287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5213
Description: AZD5213 doseB daily
Study NCT03559725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine gum (C)
Description: 4 mg nicotine gum
Study NCT04522999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: The Valeda™ Light Delivery System
Study NCT01841073 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Subjects will have 4 dietary counselling sessions in the first 9 weeks of the study with a goal to lose 5% of their body weight by week 9. They will be asked to maintain their weight loss until week 18.
Study NCT01841073 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose
Description: Subjects will have 4 dietary counselling sessions in the first 9 weeks of the study with a goal to lose 5% of their body weight by week 9. They will be asked to maintain their weight loss until week 18.
Study NCT01841073 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Subject will take inulin for 6 weeks in total with no other change to their diet or lifestyle.
Study NCT01548287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5213
Description: AZD5213 doseC daily
Study NCT01548287 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet daily
Study NCT02864602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV dexamethasone
Description: An infusion of IV dexamethasone
Study NCT02842359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan/atorvastatin fixed dose combination
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study NCT02842359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan SR47436
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study NCT02842359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study NCT04686214 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: heating
Description: patients were aggressively warmed using multiple heating methods such as pressurized air heater and intravenous fluid heater
Study NCT04640857 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Silk'n Toothwave
Description: patients will receive a non-surgical treatment which will include oral hygiene instructions, calculus removal with ultrasonic and manual instruments. At the end of the meeting they will be provided with a toothbrush which is based on a radiofrequency technology.
Study NCT04501822 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of clinical, instrumental and laboratory diagnostics tests
Description: During follow-up visits patients undergo clinical, instrumental and laboratory diagnostics tests
Study NCT04632862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001
Description: DWP16001 A mg
Study NCT04632862 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DWP16001
Description: DWP16001 A mg
Study NCT02943161 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Citrulline
Description: The purpose of this study is to see if citrulline supplementation will restore NO levels and lung function in subjects with asthma.
Study NCT00751231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: Loading dose of 300mg or 600mg, followed by once daily dosing of 75 mg
Study NCT00751231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRT060128
Description: 80-120 mg IV bolus administered prior to PCI, followed by twice daily dosing of oral 50mg, 100mg or 150mg
Study NCT03562156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oteseconazole (VT-1161)
Description: Oteseconazole (VT-1161) 150mg capsule
Study NCT03562156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo capsule
Study NCT00864279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine Hydrochloride 10 mg tablets, single dose
Description: A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fast conditions
Study NCT00864279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyrtec® 10 mg tablets, single dose
Description: B: Active comparator Subjects received Pfizer Inc. formulated products under fast conditions
Study NCT01623947 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Beverage
Description: 1400 ml flavored, colored, artificially sweetened, non-caloric beverage divided into 6 servings provided prior to and during the 2.5 hr interval ride.
Study NCT01623947 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 2.8 g Sustamine Beverage
Description: 1400 ml flavored, colored, artificially sweetened, beverage containing 2.8 g Sustamine divided into 6 servings provided prior to and during the 2.5 hr interval ride.
Study NCT01623947 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 19.6 g Sustamine Beverage
Description: 1400 ml flavored, colored, artificially sweetened, beverage containing 19.6 g Sustamine divided into 6 servings provided prior to and during the 2.5 hr interval ride.
Study NCT01407601 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: daily supplementation of MK-7 over 6 weeks
Description: once daily intake of MK-7 prior to dialysis over 6 weeks
Study NCT02687646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adult Allogeneic Mesenchymal cells from adipose tissue.
Description: Study treatment consists of Mesenchymal Stem Cell (MSC) derived from donors adipose tissue and expanded in vitro in a specific medium with platelet lysate without addition of animal derived products.~Subjects will receive four sequential IV dose of Mesenchymal stem cells.~Sequential doses:~Day 1: 0.7-1 x 106 MSC / kg Day 4: 0.7-1 x 106 MSC / kg Day 11: 0.7-1 x 106 MSC / kg Day 18: 0.7-1 x 106 MSC / kg
Study NCT01721564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: 62.5 mg Bosentan twice a day for 1 month 125 mg Bosentan twice a day for 5 months
Study NCT04252066 — intervention group
Intervention type: DRUG
Intervention: migalastat
Description: This is an observational study. Patients as described in Cohort 1 should have been exposed to at least 1 dose of migalastat during pregnancy and/or breastfeeding.
Study NCT01841073 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose
Description: Subject will take cellulose for 6 weeks in total with no other change to their diet or lifestyle.
Study NCT01841073 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Subject will take inulin for 6 weeks in total with no other change to their diet or lifestyle.~Subject will wear a Continuous Glucose Monitor for 4 x 5 days during the study.
Study NCT01841073 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose
Description: Subject will take cellulose for 6 weeks in total with no other change to their diet or lifestyle.~Subject will wear a Continuous Glucose Monitor for 4 x 5 days during the study.
Study NCT01287455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 as BABY D3
Description: drops, 70 drops (= 14000 units), once weekly for 6 weeks
Study NCT01287455 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: drops, 70 placebo drops, once weekly for 6 weeks
Study NCT02020109 — intervention group
Intervention type: RADIATION
Intervention: splenic irradiation
Study NCT01015924 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: plate osteosynthesis
Description: Patients are operated upon within 3 w of the fracture
Study NCT01015924 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESIN
Description: Elastiv stable intramedullary nailing
Study NCT03884725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fibrinogen Concentrate
Description: Fibrinogen Concentrate is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Subjects are to be given Fibrinogen Concentrate at an individually determined dose based on FIBTEM MCF and body weight as follows: (15 \[mm\] - MCF \[mm\]) \* body weight \[kg\] / 140 \[mm\*kg/g\] = gram fibrinogen to be dosed as Fibrinogen Concentrate. Fibrinogen Concentrate is to be infused over 1 to 2 minutes. After Fibrinogen Concentrate infusion, bleeding treatment will follow the predefined, standardized treatment regimen.
Study NCT03884725 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: 0.9% saline is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Patients randomized to the control group will receive the infusion of 0.9% saline (SF0,9%) prepared based on ROTEM measurement of maximum clot firmness (MCF). 0.9% saline is to be infused over 1 to 2 minutes. After 0.9% saline infusion, bleeding treatment will follow the predefined, standardized treatment regimen.
Study NCT02438540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: metformin tablet 500 mg
Study NCT03150914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sirolimus
Description: mTOR inhibitor or placebo
Study NCT03150914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: mTOR inhibitor or placebo
Study NCT02699515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB0011359C
Description: Subjects with metastatic or locally advanced solid tumors received intravenous infusion of MSB0011359C over 1 hour once every two weeks for up to 12 months until confirmed progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product (IMP) occurs.
Study NCT02438540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: metformin tablet 500 mg
Study NCT02438540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Electro body acupuncture and auricular acupuncture
Study NCT01085578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CG400549/placebo
Description: Period 1: a single oral dose of 80 mg CG400549 or placebo on Day 1 Period 2: a single oral dose of 320 mg CG400549 or placebo on Day 1 Period 3: a single oral dose of 1280 mg CG400549 or placebo on Day 1
Study NCT01085578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CG400549/placebo
Description: Period 1: a single oral dose of 160 mg CG400549 or placebo on Day 1 Period 2: a single oral dose of 640 mg CG400549 or placebo on Day 1 Period 3: a single oral dose of 1920 mg CG400549 or placebo on Day 1
Study NCT01085578 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CG400549
Description: Period 1: a single oral dose of 640 mg CG400549 on Day 1 in the fasted state Period 2: a single oral dose of 640 mg CG400549 on Day 1 in the fed state
Study NCT03245216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: Single-bout of moderate intensity aerobic exercise on a cycle ergometer before motor learning
Study NCT03245216 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: rest
Description: Seated rest before motor learning
Study NCT03245216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motor learning
Description: Motor learning task on a stability platform (Stabilometer). Participants try to keep the tiltable platform in an horizontal position.
Study NCT03245216 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: motor learning
Description: Motor learning task on a stability platform (Stabilometer). Participants try to keep the tiltable platform in an horizontal position.
Study NCT00402519 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation
Description: APBI with PDR and HDR brachytherapy
Study NCT00402519 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External beam whole breast irradiation
Description: Standard Whole breast irradiation
Study NCT01269476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNX-001
Description: 3.6, 7.2, or 10.8 mg single dose or t.i.w.
Study NCT01269476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same volumes and frequency as active.
Study NCT04385095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SNG001
Description: SNG001 via inhalation
Study NCT04298840 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate Supplementation
Description: Participants in the creatine monohydrate supplementation arm will consume 5 grams per day of creatine monohydrate.
Study NCT04298840 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Supplementation
Description: Participants in the placebo supplementation arm will consume 5 grams per day of maltodextrin placebo.
Study NCT03628079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ReposMBZ
Description: Capsules 50mg, 100mg, 200mg
Study NCT00507637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201
Description: Injection of up to 50 Units NT 201 (incobotulinumtoxinA/Xeomin®) per eye and injection visit (8 injections visits in total).
Study NCT03255018 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered intravenously (IV) at a fixed dose of 200 mg every 3 weeks until disease progression or unacceptable toxicity; treatment may continue indefinitely if clinical benefit with options for treatment interruption if responding disease and re-treatment upon relapse.
Study NCT06068166 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TEA plus GDMT
Description: Thoracic epidural anesthesia (TEA), the infusion of anesthetic agents (eg, lidocaine or ropivacaine) into the epidural space, is used to achieve sympathetic block at the T1 to T4 levels in thoracic and abdominal surgical procedures. Since 1995, Professor Liu Fengqi has pioneered the use of TEA to treat end-stage HFrEF and achieved surprising results. TEA could reduce the enlarged heart cavity, halt and reverse cardiac remodeling, and improve cardiac systolic and diastolic function. Currently, thousands of HFrEF patients have received TEA procedure. All the patients received maximally tolerated guideline-directed medical therapy (GDMT).